Results 31 to 40 of about 968,402 (255)

lowest observed adverse effect level

, 2014
Citation: 'lowest observed adverse effect level' in the IUPAC Compendium of Chemical Terminology, 3rd ed.; International Union of Pure and Applied Chemistry; 2006. Online version 3.0.1, 2019. 10.1351/goldbook.LT06909 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire   +2 more sources

Bridging the Loneliness Gap: Depression, Connectivity, and Isolation in Pediatric Oncology Patients and Their Peers

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Loneliness is associated with adverse physical and mental health outcomes and remains understudied in children and adolescents undergoing cancer therapy. Pediatric oncology patients may be at increased risk due to medical isolation and disruption of social networks.
Charlotte N. Stahlfeld, Scott H. Maurer, Michelle D. Watkinson, John Nury, Elise Barberis, Molly C. Mack   +5 more
wiley   +1 more source

Central Nervous System Tumors Among Infants in Canada: A Report From CYP‐C

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) tumors in infants are rare, pose unique clinical challenges, and lack large‐scale evidence‐based data to guide management. This study seeks to describe CNS tumors in Canadian infants and to compare their outcomes with those of older children.
Samuel Sassine, Hallie Coltin, Sylvia Cheng, Lucie Lafay‐Cousin, Vanan Issai Magimairajan, Craig Erker, Stéphanie Vairy, Lynette Bowes, Adam Fleming, Donna Johnston, Sarah McKillop, Roona Sinha, Julie Bennett, Christina Coleman, Laura Wheaton, Shayna Zelcer, Samuele Renzi, Thai Hoa Tran   +17 more
wiley   +1 more source

Impact of Radiation Therapy on Physical and Psychosocial Health of Adolescents and Young Adults: A Joint Report From the Children's Oncology Group AYA and Radiation Oncology Committees

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Rates of cancer among adolescents and young adults (AYA), age 15–39 years, are increasing. Consequently, radiation oncologists are treating more AYAs who have diagnoses spanning both pediatric and adult practices. Compared to pediatric and older adult patients, AYAs face a unique set of challenges.
Hesham Elhalawani, Rachel K. Peterson, Avani D. Rao, Laurie J. McKenzie, Ahmed Magdy Elmotayam, Leslie Chang, Michael Roth, Susan L. McGovern   +7 more
wiley   +1 more source

Subchronic oral toxicity and in vitro anti-neuroinflammatory evaluation of Ficus erecta leaves extract for potential functional food applications

Toxicology Reports
Ficus erecta leaves, a traditional medicinal plant that is widely used in East Asia, have demonstrated promising cognitive-enhancing effects. However, the safety of its long-term administration has not been elucidated.
Eunjin Sohn, Yu Jin Kim, Woo-Young Jeon, Sae-Rom Yoo, Kyuhyung Jo, Ami Lee, Aejin Kim, Jin Ah Ryuk, Chan-Sik Kim, Bu-Yeo Kim, Mee-Young Lee, Hye-Sun Lim, Youn-Hwan Hwang, Soo-Jin Jeong   +13 more
doaj   +1 more source

26-Week Repeated Dose Oral Toxicity Study of KCHO-1 in Sprague-Dawley Rats

Journal of Pharmacopuncture, 2019
Objectives: KCHO-1(Mecasin), also called Gamijakyakgamchobuja-tang originally, is a combination of some traditional herbal medicines in East Asia. This medicine has been used mainly for alleviating neuropathic pains for centuries in Korean traditional ...
Muhack Yang, Seongjin Lee, Tingting Wang, Eunhye Cha, Jongwon Jang, Dongwoung Kim, Bong-Keun Song, Ilhong Son, Joonyup Kim, Hyung Won Kang, Sungchul Kim   +10 more
doaj   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan S. Lim, Gordan Srkalovic, Frits van Rhee, David C. Fajgenbaum, Joshua D. Brandstadter   +17 more
wiley   +1 more source

Safety, immunogenicity of lyophilized purified vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post-exposure subjects: A post-marketing, parallel control clinical trial

Human Vaccines & Immunotherapeutics, 2021
To compare the safety and immunogenicity of lyophilized PVRV under Zagreb and Essen regimen. A post-marketing parallel control clinical trial was conducted.
Lei Zhang, Shichun Huang, Li Cai, Zhenggang Zhu, Jian Chen, Sha Lu, Zerong Zhu, Man Zhang, Yuan Fang, Quan Hu   +9 more
doaj   +1 more source

Dietary administration of β-ionone epoxide to Sprague-Dawley rats for 90 days

Current Research in Toxicology, 2021
In a 90-day GLP-compliant study groups of Sprague-Dawley rats (10/sex/group) were fed diets containing β-ionone epoxide, a fragrance material and a flavoring substance, at dietary concentrations providing target intakes of 0, 20, 40 and 80 mg/kg bw/day ...
Vivian Lu, Maria Bastaki, Anne Marie Api, Michel Aubanel, Mark Bauter, Thierry Cachet, Jan Demyttenaere, Maodo Malick Diop, Christie L. Harman, Shim-mo Hayashi, Gerhard Krammer, Odete Mendes, Kevin J. Renskers, Jürgen Schnabel, Sean V. Taylor   +14 more
doaj   +1 more source

no observed adverse effect level

, 2014
Citation: 'no observed adverse effect level' in the IUPAC Compendium of Chemical Terminology, 3rd ed.; International Union of Pure and Applied Chemistry; 2006. Online version 3.0.1, 2019. 10.1351/goldbook.NT06911 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms ...
openaire   +1 more source